Alongside, MSI‐1436, a reversible inhibitor of Ptp1b, is an experimental drug candidate that has similarly been regarded as a powerful modulator of metabolic diseases in mammals, with Phase II clinical trials further demonstrating its efficacy in treating obesity and T2DM (Bourebaba, Serwotka‐Suszczak, Bourebaba, et al., 2023; Cho, 2013; Takahashi et al., 2004). Here, PTPN1 is linked to metabolic disease.